The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: TAGGED—A phase 2 study using low dose/metronomic trabectedin, gemcitabine, and dacarbazine as 2nd/3rd/4th line therapy for advanced soft tissue sarcoma (NCT04535271).
 
Samantha Jeffrey
No Relationships to Disclose
 
Jason Ballon
No Relationships to Disclose
 
Anmol Agarwal
No Relationships to Disclose
 
Lauren Woolsey
No Relationships to Disclose
 
Princess "Angela" Savage
No Relationships to Disclose
 
Vanessa Xayasak
No Relationships to Disclose
 
Sarosh Syed
No Relationships to Disclose
 
Victoria Chua-Alcala
No Relationships to Disclose
 
Ania Moradkhani
No Relationships to Disclose
 
Doris Quon
No Relationships to Disclose
 
Steve Wong
No Relationships to Disclose
 
Neal Chawla
No Relationships to Disclose
 
Erlinda Gordon
Leadership - Counterpoint Biomedica; Delta Next-Gene, LLC
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Research Funding - Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
Travel, Accommodations, Expenses - Immix BioPharma
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma